Healthcare industry

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.

Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.

Article - 23/04/2019

How can care infrastructures benefit from digitization?

The pilot project NeCTra (Networking - Care - Transparency) investigates how care processes within an urban social environment can be improved by using digital technologies. The goal is to bring together all partners and institutions in real time so that people in need of care and those seeking advice receive appropriate support more quickly.

Article - 11/04/2019

Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.

Article - 18/03/2019

EHR and PHR: digital records in the German healthcare system

EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.

Article - 24/01/2019

Scientists to combat antibiotic-resistant bacteria in wastewater

In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

Article - 10/01/2019

Stocktaking and recommendations for action: the BBAW’s fourth gene technology report

In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…

Press release - 10/12/2018

High distinction for stem cell researcher Andreas Trumpp

This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.

Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…

Article - 19/11/2018

Tobacco for health

Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.

Article - 30/10/2018

Eucor – bringing the European Campus to life

Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences.

Article - 29/10/2018

Aminolipine: formaldehyde-free substitute for preserving biological tissues

For almost 125 years, undertakers as well as physicians in the fields of anatomy and pathology have used formaldehyde to preserve biological tissue and whole cadavers. Yet, formaldehyde is highly toxic and linked to cancer. A team led by Prof. Dr. Bernhard Hirt from the Institute of Clinical Anatomy and Cell Analysis at the University Hospital in Tübingen has developed a formaldehyde-free replacement substance.

University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.

Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…

Dossier - 28/08/2018

With molecular diagnostics to biomarker-based personalised therapy

Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.

The European Research Council (ERC) awards Starting Grants to support excellent young scientists when they are starting an independent science career. In this year's round of proposals, three scientists from the German Cancer Research Center (DKFZ) have been chosen at once for the prestigious award: Ana Banito, Fabian Erdel and Moritz Mall.

Article - 14/08/2018

Simple and fast: new optical method for analysing living cells

The junior researchers Dr. Daniel Geiger, Tobias Neckernuß and Jonas Pfeil from Ulm have developed an innovative method for non-contact real-time analysis of cells and other particles. The analysis involves low data rates and correspondingly little effort. This is what makes the method so attractive for medical applications.

Article - 31/07/2018

Acousia Therapeutics: medicines for deafness

Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.

Article - 26/07/2018

evid - therapy recommendations at a glance

There are over 700 treatment guidelines in Germany alone, and each is up to several hundred pages long. Can doctors still stay on top of things? A start-up company from Mannheim called evid is developing a software that can retrieve relevant therapy recommendations for individual patients from the huge pile of paperwork. In March 2018, the founding trio won first place of the eHealthForum Freiburg start-up competition.

SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over €90 million in its fifth fund's first closing. The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong players, especially in Germany and Switzerland.

Article - 13/06/2018

TeleDerm: Rapid help from a dermatologist via teleconsultation

Some geographical locations have relatively few specialist medical practices. Getting an appointment with a specialist if you live in such areas might mean a long wait or a long journey. A study being carried out at the University of Tübingen is looking to improve this situation: the TeleDerm project involves dermatologists using telemedicine to assess skin disorders from images taken by GPs.